The global critical limb ischemia treatment market size is expected to reach US$ 2.81 bn bn 2027 and is projected to expand at a high CAGR of 7.6% from 2020 to 2027. Rise in prevalence of critical limb ischemia across the world is anticipated to drive the global market during the forecast period.
Increase in Preference for Revascularization as Treatment Option to Drive Devices Segment
In terms of treatment, the devices segment is projected to account for dominant share of the global critical limb ischemia treatment market during the forecast period. The segment is anticipated to expand at a high CAGR from 2018 to 2026. Dominance of the segment is attributed to increase in patient preference for revascularization as the first line of treatment. The medications segment held major share of the market in 2018, followed by the devices segment, due to increase in acceptance and availability of antiplatelet drugs, lipid-lowering agents, and other medications.
Peripheral Dilatation Systems Sub-segment Dominated the Devices Segment
The report offers detailed segmentation of the global critical limb ischemia treatment market. The devices segment has been classified into embolic protection devices and peripheral dilatation systems. The peripheral dilatation systems sub-segment is projected to account for leading share of the segment during the forecast period. Higher share of the segment is attributed to increasing use of balloon dilators and vascular stents in the treatment of CLI. According to recent study, around 2 million to 3 million people suffer from critical limb ischemia in the U.S.
High Preference for Antiplatelet Drugs to Treat Critical Limb Ischemia
The antiplatelet drugs sub-segment accounted for leading share of the medications segment in 2018. The sub-segment is projected to lose market share from 2019 to 2027. The sub-segment is anticipated to expand at a CAGR of 7.8% during the forecast period. Antiplatelet drugs are most widely used in the treatment of critical limb ischemia and easily available in retail stores. Additionally, major pharmaceutical manufacturers focus on the development of new antiplatelet drugs for treatment of critical limb ischemia. This is likely to fuel the growth of the sub-segment during the forecast period. Lipid-lowering agents was a major sub-segment of the medications segment in 2018, followed by the antiplatelet drugs sub-segment.
Asia Pacific to be Highly Lucrative Market
The critical limb ischemia treatment market in Asia Pacific is driven by rise in prevalence of CLI in countries such as India and China, increase in geriatric population, surge in health care spending, and government initiatives. High population, unmet medical needs, and rise in patient awareness are also anticipated to propel the market in the region. Economic growth in emerging economies such as India and China is enhancing the buying capabilities of consumers due to an increase in disposable income. This is likely to augment the market in these countries in the near future.
Trend of Strategic Alliance with Local Companies to Strengthen Distribution Network and Expand Geographic Presence
The global critical limb ischemia treatment market is fragmented, owing to the presence of several small and large companies. However, the market is dominated by a few major players with strong global presence. The report provides profiles of leading players operating in the global critical limb ischemia treatment market. Key players in the market include Medtronic plc, Boston Scientific Corporation, Cesca Therapeutics Inc., Abbott Laboratories, Pluristem Therapeutics Inc., Rexgenero Ltd, LimFlow SA, Micro Medical Solutions, and Cardiovascular Systems, Inc.
The report analyzes and forecasts the critical limb ischemia treatment market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of critical limb ischemia treatment, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major critical limb ischemia treatment companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of critical limb ischemia treatment upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of critical limb ischemia treatment and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global critical limb ischemia treatment market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the critical limb ischemia treatment market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of critical limb ischemia treatment market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Major players operating in the global critical limb ischemia treatment market include Medtronic plc, Boston Scientific Corporation, Cesca Therapeutics, Inc., Abbott Laboratories, Pluristem Therapeutics, Inc., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, and Cardiovascular Systems, Inc. These companies have adopted the strategy of acquisition and collaboration to strengthen their positions in the global market.
The global critical limb ischemia treatment market has been segmented as below:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers and Restraints Snapshot Analysis
4.2.2. Drivers
4.2.3. Restraints
4.2.4. Opportunity
4.3. Global Critical Limb Ischemia Treatment Market Revenue Projection (US$ Mn), 2017–2026
4.4. Global Critical Limb Ischemia Treatment Market Outlook
5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Industry Events
5.3. Regulatory Scenario for Device
5.4. Prevalence of Critical Limb Ischemia Globally/Region
5.5. Major Research Institutes Involved
5.6. Technological Advancement
6. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment
6.1. Key Findings
6.2. Introduction
6.3. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
6.4. Global Critical Limb Ischemia Treatment Market Forecast, by Treatment
6.4.1. Devices
6.4.1.1. Embolic Protection Devices
6.4.1.2. Peripheral Dilatation Systems
6.4.1.2.1. Balloon Dilators
6.4.1.2.2. Vascular stents
6.4.2. Medications
6.4.2.1. Antiplatelet Drugs
6.4.2.2. Antihypertensive Agents
6.4.2.3. Lipid-lowering Agents
6.4.2.4. Antithrombotic Agents
6.4.2.5. Others
6.5. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment
7. Global Critical Limb Ischemia Treatment Market Analysis, by Region
7.1. Global Critical Limb Ischemia Treatment Market Scenario, by Country
7.2. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Region
7.3. Global Critical Limb Ischemia Treatment Market Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
8. North America Critical Limb Ischemia Treatment Market Analysis
8.1. Key Findings
8.2. North America Critical Limb Ischemia Treatment Market Overview
8.3. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country
8.4. North America Critical Limb Ischemia Treatment Market Forecast, by Country
8.4.1. U.S.
8.4.2. Canada
8.5. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
8.6. North America Critical Limb Ischemia Treatment Market Forecast, by Treatment
8.6.1. Devices
8.6.1.1. Embolic Protection Devices
8.6.1.2. Peripheral Dilatation Systems
8.6.1.2.1. Balloon Dilators
8.6.1.2.2. Vascular stents
8.6.2. Medications
8.6.2.1. Antiplatelet Drugs
8.6.2.2. Antihypertensive Agents
8.6.2.3. Lipid-lowering Agents
8.6.2.4. Antithrombotic Agents
8.6.2.5. Others
9. Europe Critical Limb Ischemia Treatment Market Analysis
9.1. Key Findings
9.2. Europe Critical Limb Ischemia Treatment Market Overview
9.3. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
9.4. Europe Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
9.4.1. Germany
9.4.2. France
9.4.3. U.K.
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
9.6. Europe Critical Limb Ischemia Treatment Market Forecast, by Treatment
9.6.1. Devices
9.6.1.1. Embolic Protection Devices
9.6.1.2. Peripheral Dilatation Systems
9.6.1.2.1. Balloon Dilators
9.6.1.2.2. Vascular stents
9.6.2. Medications
9.6.2.1. Antiplatelet Drugs
9.6.2.2. Antihypertensive Agents
9.6.2.3. Lipid-lowering Agents
9.6.2.4. Antithrombotic Agents
9.6.2.5. Others
10. Asia Pacific Critical Limb Ischemia Treatment Market Analysis
10.1. Key Findings
10.2. Asia Pacific Critical Limb Ischemia Treatment Market Overview
10.3. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.4. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
10.6. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Treatment
10.6.1. Devices
10.6.1.1. Embolic Protection Devices
10.6.1.2. Peripheral Dilatation Systems
10.6.1.2.1. Balloon Dilators
10.6.1.2.2. Vascular stents
10.6.2. Medications
10.6.2.1. Antiplatelet Drugs
10.6.2.2. Antihypertensive Agents
10.6.2.3. Lipid-lowering Agents
10.6.2.4. Antithrombotic Agents
10.6.2.5. Others
11. Latin America Critical Limb Ischemia Treatment Market Analysis
11.1. Key Findings
11.2. Latin America Critical Limb Ischemia Treatment Market Overview
11.3. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Latin America Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
11.6. Latin America Critical Limb Ischemia Treatment Market Forecast, by Treatment
11.6.1. Devices
11.6.1.1. Embolic Protection Devices
11.6.1.2. Peripheral Dilatation Systems
11.6.1.2.1. Balloon Dilators
11.6.1.2.2. Vascular stents
11.6.2. Medications
11.6.2.1. Antiplatelet Drugs
11.6.2.2. Antihypertensive Agents
11.6.2.3. Lipid-lowering Agents
11.6.2.4. Antithrombotic Agents
11.6.2.5. Others
12. Middle East & Africa Critical Limb Ischemia Treatment Market Analysis
12.1. Key Findings
12.2. Middle East & Africa Critical Limb Ischemia Treatment Market Overview
12.3. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
12.6. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Treatment
12.6.1. Devices
12.6.1.1. Embolic Protection Devices
12.6.1.2. Peripheral Dilatation Systems
12.6.1.2.1. Balloon Dilators
12.6.1.2.2. Vascular stents
12.6.2. Medications
12.6.2.1. Antiplatelet Drugs
12.6.2.2. Antihypertensive Agents
12.6.2.3. Lipid-lowering Agents
12.6.2.4. Antithrombotic Agents
12.6.2.5. Others
13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profile
13.2.1. Medtronic plc
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Financial Overview
13.2.1.3. Product Portfolio
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.2. Boston Scientific Corporation
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Financial Overview
13.2.2.3. Product Portfolio
13.2.2.4. SWOT Analysis
13.2.2.5. Strategic Overview
13.2.3. Cesca Therapeutics, Inc.
13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.3.2. Financial Overview
13.2.3.3. Product Portfolio
13.2.3.4. SWOT Analysis
13.2.3.5. Strategic Overview
13.2.4. Abbott Laboratories
13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.4.2. Financial Overview
13.2.4.3. Product Portfolio
13.2.4.4. SWOT Analysis
13.2.4.5. Strategic Overview
13.2.5. Pluristem Therapeutics, Inc.
13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.5.2. Financial Overview
13.2.5.3. Product Portfolio
13.2.5.4. SWOT Analysis
13.2.5.5. Strategic Overview
13.2.6. Rexgenero Ltd.
13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.6.2. Financial Overview
13.2.6.3. Product Portfolio
13.2.6.4. SWOT Analysis
13.2.6.5. Strategic Overview
13.2.7. LimFlow SA
13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.7.2. Financial Overview
13.2.7.3. Product Portfolio
13.2.7.4. SWOT Analysis
13.2.7.5. Strategic Overview
13.2.8. Micro Medical Solutions
13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.8.2. Financial Overview
13.2.8.3. Product Portfolio
13.2.8.4. SWOT Analysis
13.2.8.5. Strategic Overview
13.2.9. Cardiovascular System, Inc.
13.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.9.2. Financial Overview
13.2.9.3. Product Portfolio
13.2.9.4. SWOT Analysis
13.2.9.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers